Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Instead of waiting years for traditional vision preservation data, Complement Therapeutics' trial prospectively uses novel endpoints like ellipsoid zone attenuation and focal microperimetry. These measures are designed to show a signal of efficacy earlier and correlate better with functional outcomes, addressing a key challenge in slowly progressing diseases.

Coya Therapeutics' vision is to make diseases like ALS "livable" by completely stopping their progression. This ambitious goal stems from a small investigator-initiated trial where patients showed no disease progression over six months, a period where a significant decline is typically expected, reframing the therapeutic benchmark.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

After a decade on the market and multiple shifts in endpoints, Sarepta's definitive Phase 3 study for its DMD drugs failed. This outcome casts doubt on the entire accelerated approval framework for slowly progressive diseases, where surrogate endpoints may not translate to clinical benefit, leaving regulators and patients in a difficult position.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

The company's clinical trials go beyond standard pain scores to track improvements in function, sleep, and patient satisfaction. Demonstrating that patients can climb stairs, drive, and sleep better provides a more compelling value proposition for a faster return to normal life, resonating with patients, surgeons, and payers alike.